Inventor · disambiguated record
Jennifer R. Lo
Also filed as: LO JENNIFER R · LO JENNIFER REBECCA
21 granted patents·5 pending applications·99 citations·filing 2006–2023
94Inventor score
Top patents by PatentIndex Score
26 records- 0197US9290505B2Substituted imidazo[1,2-a]pyrazines as Syk inhibitorsGILEAD SCIENCES INC·Filed 2014·Granted Mar 22, 2016·23 cites·36 claims
- 0295US9504684B2Syk inhibitorsGILEAD SCIENCES INC·Filed 2015·Granted Nov 29, 2016·18 cites·30 claims
- 0393US11897878B2Substituted 6-azabenzimidazole compoundsGILEAD SCIENCES INC·Filed 2021·Granted Feb 13, 2024·2 cites·65 claims
- 0492US11925631B2Substituted 6-azabenzimidazole compoundsGILEAD SCIENCES INC·Filed 2021·Granted Mar 12, 2024·2 cites·37 claims
- 0591US9968601B2Substituted imidazo[1,2-a]pyrazines as Syk inhibitorsGILEAD SCIENCES INC·Filed 2016·Granted May 15, 2018·7 cites·53 claims
- 0691US9376441B2Substituted pyrrolidines as SYK inhibitorsGILEAD SCIENCES INC·Filed 2014·Granted Jun 28, 2016·17 cites·20 claims
- 0790US10342794B2Substituted imidazo[1,2-a]pyrazines as Syk inhibitorsGILEAD SCIENCES INC·Filed 2018·Granted Jul 9, 2019·5 cites·15 claims
- 0889US11071730B2Substituted 6-azabenzimidazole compoundsGILEAD SCIENCES INC·Filed 2019·Granted Jul 27, 2021·4 cites·40 claims
- 0988US11203591B2Substituted 6-azabenzimidazole compoundsGILEAD SCIENCES INC·Filed 2019·Granted Dec 21, 2021·6 cites·45 claims
- 1088US10040781B2Tank-binding kinase inhibitor compoundsGILEAD SCIENCES INC·Filed 2015·Granted Aug 7, 2018·3 cites·48 claims
- 1187US11517570B2Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amineKRONOS BIO INC·Filed 2020·Granted Dec 6, 2022·1 cites·22 claims
- 1287US10828299B2Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amineGILEAD SCIENCES INC·Filed 2019·Granted Nov 10, 2020·3 cites·18 claims
- 1384US12263163B2Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitorKRONOS BIO INC·Filed 2022·Granted Apr 1, 2025·0 cites·19 claims
- 1483US10005774B2Syk inhibitorsGILEAD SCIENCES INC·Filed 2016·Granted Jun 26, 2018·4 cites·9 claims
- 1583US9931338B2Syk inhibitorsGILEAD SCIENCES INC·Filed 2016·Granted Apr 3, 2018·3 cites·20 claims
- 1678US12258346B2Substituted 6-azabenzimidazole compoundsGILEAD SCIENCES INC·Filed 2023·Granted Mar 25, 2025·0 cites·23 claims
- 1770US7723329B2Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligandsWYETH LLC·Filed 2006·Granted May 25, 2010·1 cites·22 claims
- 1864US12410160B2KHK inhibitorsGILEAD SCIENCES INC·Filed 2022·Granted Sep 9, 2025·0 cites·38 claims
- 1959US10253019B2Tank-binding kinase inhibitor compoundsGILEAD SCIENCES INC·Filed 2018·Granted Apr 9, 2019·0 cites·13 claims
- 2059US7482461B2Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligandsWYETH CORP·Filed 2007·Granted Jan 27, 2009·0 cites·12 claims
- 2159US2009105303A1Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligandsWYETH CORP·Filed 2008·Application pending·0 cites
- 2255US2009318470A11-substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1h-indazole compounds as 5-hydroxytryptamine-6 ligandsWYETH CORP·Filed 2009·Application pending·0 cites
- 2355US2018280387A1Syk inhibitorsGILEAD SCIENCES INC·Filed 2018·Application pending·0 cites
- 2447US2007281922A11-Sulfonylindazolylamine and - amide derivatives as 5-hydroxytryptamine-6 ligandsWYETH CORP·Filed 2007·Application pending·0 cites
- 2545US7790751B2Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligandsWYETH LLC·Filed 2006·Granted Sep 7, 2010·0 cites·14 claims
- 2643US2013338142A1Imidazopyrazine syk inhibitorsGILEAD CONNECTICUT INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jennifer R. Lo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →